th9507 and Hip-Fractures

th9507 has been researched along with Hip-Fractures* in 1 studies

Reviews

1 review(s) available for th9507 and Hip-Fractures

Article	Year
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:10 Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin. Topics: Adjuvants, Immunologic; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cognition Disorders; Contraindications; Diabetes Mellitus, Type 2; Growth Hormone-Releasing Hormone; Hip Fractures; HIV Wasting Syndrome; HIV-Associated Lipodystrophy Syndrome; Humans; Lipid Metabolism; Peptides; Recombinant Proteins; Sleep Wake Disorders; Structure-Activity Relationship	2006

Article

Year

Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.

Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:10

Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin.

Topics: Adjuvants, Immunologic; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cognition Disorders; Contraindications; Diabetes Mellitus, Type 2; Growth Hormone-Releasing Hormone; Hip Fractures; HIV Wasting Syndrome; HIV-Associated Lipodystrophy Syndrome; Humans; Lipid Metabolism; Peptides; Recombinant Proteins; Sleep Wake Disorders; Structure-Activity Relationship

2006